The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?
Biomolecules · 05.09.2025 · 15 (9) · 1284
DOI: 10.3390/biom15091284 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 05.09.2025. Verfasst von Dimitris Kounatidis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Ho…. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Erectile Dysfunction, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 215 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Erectile dysfunction (ED) is a common yet frequently underrecognized microvascular complication of diabetes, affecting up to three out of four individuals. Key contributing factors include advancing age, long-standing disease duration, and suboptimal glycemic control, as well as insulin resistance and androgen deficiency—the latter being particularly common in men with type 2 diabetes (T2D) and obesity. While numerous studies have investigated the effects of various antidiabetic therapies on diabetes-related ED, the results remain inconsistent, limiting definitive conclusions. In recent years, increasing attention has focused on a novel class of antidiabetic medications, namely glucagon-like peptide-1 receptor agonists (GLP-1 RAs). These agents have become central to the treatment of T2D due to their potent glucose-lowering properties and well-documented benefits on cardiovascular outcomes, and weight loss. Given these pleiotropic effects, GLP-1 RAs have been presumed to positively influence erectile function—a hypothesis supported by a growing body of experimental and clinical research. However, preliminary reports have also raised concerns about a possible association between GLP-1 RA use and ED. This narrative review aims to synthesize current evidence regarding the impact of GLP-1 RAs on erectile function, providing a platform for future research in this evolving field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece.
- First Department of Internal Medicine, Sismanogleio General Hospital, 15126 Athens, Greece.
- Turku PET Centre, University of Turku, 20014 Turku, Finland.
- Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
- Clinic of Nephrology and Renal Transplantation, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece.
ORCID-Profile: Dimitris Kounatidis, Natalia G Vallianou, Konstantinos Makrilakis, Nikolaos Tentolouris
Zitieren
APA
Kounatidis, D., Vallianou, N. G., Rebelos, E., Vallianou, K., Diakoumopoulou, E., Makrilakis, K., & Tentolouris, N. (2025). The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?. Biomolecules, 15(9), 1284. https://doi.org/10.3390/biom15091284
Vancouver
Kounatidis D, Vallianou NG, Rebelos E, Vallianou K, Diakoumopoulou E, Makrilakis K, et al. The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?. Biomolecules. 2025;15(9):1284. doi:10.3390/biom15091284
BibTeX
@article{Kounatidis2025,
author = {Kounatidis, Dimitris and Vallianou, Natalia G and Rebelos, Eleni and Vallianou, Kalliopi and Diakoumopoulou, Evanthia and Makrilakis, Konstantinos and Tentolouris, Nikolaos},
title = {The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?},
journal = {Biomolecules},
year = {2025},
volume = {15},
number = {9},
pages = {1284},
doi = {10.3390/biom15091284}
}
EUVIMED